“Our goal is to positively impact lives and health through science, and today’s inauguration exemplifies this commitment by adding physical capacity and expanding our regional network to meet the growing needs of our customers and ensuring supply chain security,” said Matthias HeinzelMember of the Management Board of Merck KGaA, Darmstadt, Germany, and CEO Life Sciences. “This new state-of-the-art facility will support the increased demand our global in vitro diagnostics manufacturing customers are experiencing.

“From rapid COVID-19 tests to cancer therapies, MilliporeSigma’s work helps promote the health and safety of our families and communities while creating good jobs for hard-working Wisconsin workers, and I’m glad to celebrate their success today,” Governor Evers said. . “In addition to creating 60 new jobs in Sheboyganthis new facility will be a major step forward in the expansion of national diagnostic testing as the company’s first lateral flow membrane production facility in the United States, ensuring our state and country is prepared for any public health crisis facing us now and in the future.”

Once constructed, the lateral flow membrane facility will be MilliporeSigma’s first facility to United States capable of producing a diagnostic grade membrane. Its location further enhances the company’s competitive advantage in the market with improved security of supply and reduced delivery times for global customers. The lateral flow membrane production line in Sheboygan completes the global capacity network of the Life Science business area of ​​Merck KGaA, Darmstadt, Germany, by adding redundant capacities to its two production lines in Cork, Irelandthereby mitigating supply chain risks.

“This new facility will expand much-needed access to critical raw materials for the world’s most sophisticated diagnostics manufacturers. Our best-in-class lateral flow membranes deliver the quality and consistency needed as manufacturers prepare for new regulations for in vitro diagnostics and medical devices,” said Jean-Charles WirthHead of Science and Lab Solutions, Life Science business of Merck KGaA, Darmstadt, Germany.

Broadband More™ The lateral flow membrane enables reproducible results thanks to its consistent quality and optimized properties. Point-of-care rapid test kits developed by the company’s customers are used for a variety of applications, including testing for infectious diseases (e.g., Covid-19, HIV, influenza, malaria), as well as pregnancy testing, biomarker detection, drug testing, food safety and animal health.

The Life Science business area of ​​Merck KGaA, Darmstadt, Germany, continues to invest in products and technologies in its portfolio that are essential to the manufacture of new therapies, vaccines and diagnostics. All expansions and investments are part of an ambitious multi-year program to increase the industrial capacity and capabilities of the life sciences business sector to support the growing global demand for lifesaving medicines and to contribute significant to public health. Recent announcements have been made in Verona, WisconsinUNITED STATES; Jaffrey, New Hampshire, UNITED STATES; and Danvers, Mass.UNITED STATES; Carlsbad, CaliforniaUNITED STATES; Cork, Ireland: Wuxi, China; Darmstadt, Germany; Logs, Swiss; Molsheim, France.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany press releases are distributed by e-mail as soon as they are available on the EMD Group website. If you reside in the United States or Canada please go to www.emdgroup.com/subscribe to re-register for your online subscription to this service, as our new geo-targeting requires new links in the email. You can later change your selection or discontinue this service.

About the Life Sciences Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germanywhich operates as MilliporeSigma in the United States and Canada, has more than 26,000 employees and 55 manufacturing and test sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germanya leading science and technology company, operates in healthcare, life sciences and electronics.

More than 60,000 employees work every day to make a positive difference in the lives of millions of people by creating more joyful and sustainable lifestyles. From advancing gene-editing technologies and discovering unique ways to treat the toughest diseases to enabling device intelligence, the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany generated a turnover of 19.7 billion euros in 66 countries.

The company owns the global rights to the “Merck” name and trademark internationally. The only exceptions are United States and Canadawhere the business areas of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life sciences and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been at the heart of the company’s technological and scientific advancements. To this day, the founding family remains the majority shareholder of the listed company. For more information about Merck KGaA, Darmstadt, Germanyvisit www.emdgroup.com.

All Merck KGaA, Darmstadt, Germany press releases are distributed by e-mail as soon as they are available on the EMD Group website. If you reside in the United States or Canada please go to www.emdgroup.com/subscribe to re-register for your online subscription to this service, as our new geo-targeting requires new links in the email. You can later change your selection or discontinue this service.

SOURCEMilliporeSigma